IDEAYA Biosciences, Inc. (IDYA) Stock Score, Valuation & Financial Research
IDEAYA Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 32/100.
Quick answer for IDYA
IDEAYA Biosciences, Inc. currently has a Wall Street Score of 32/100. The stored market price is $37.45. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What IDEAYA Biosciences, Inc. does
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inh
IDYA financial snapshot
- Wall Street Score:
- 32/100
- Current price:
- $37.45
- Market capitalization:
- $3.56B
- Revenue:
- $234.1M
- Net income:
- $-175.0M
- Free cash flow:
- $-73.5M
- Cash:
- $272.6M
- Total debt:
- $29.3M
- EPS:
- -1.28
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 28/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $-73.5M, showing cash burn in the current stored period.
- The balance sheet shows $272.6M of cash versus $29.3M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is +0.6 points: IDYA increased 0.6 points because Revenue improved by 4 points, Asset improved by 2.4 points.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IDYA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.